Therapeutic Cancer Vaccines Overview

  • ID: 4375354
  • Drug Pipelines
  • 100 Pages
  • iOnco-analytics
1 of 4
Ecommended to Any Client Wishing to Understand Quickly the Commercial Landscape of the Therapeutic Cancer Vaccine Field Within the Overview Dynamic of Cancer Immunotherapy

FEATURED COMPANIES

  • Advantagene Inc
  • Bavarian Nordic
  • Bioven
  • Gradalis
  • Northwest Biotherapeutics
  • OSE Immunotherapeutics
  • MORE

This report consists of a detailed Executive presentation (~100 slides) and MS-Excel work book summarizing current approaches in cancer immunotherapy with an in-depth focus on the therapeutic cancer vaccine category. Included is an analysis of over 300 verified cancer vaccine programs (Phase I-III) delineated by sponsor, sponsor type, mechanism, tumour type, results, and other relevant fields. Detailed case studies are presented for the identified late stage (Phase III) industry sponsored programs e.g. PROSTVAC® Bavarian Nordic with presentation of clinical trial data relevant to the Provenge® (Sipuleucel-T) reference for FDA approval. This analysis is recommended to any client wishing to understand quickly the commercial landscape of the therapeutic cancer vaccine field within the overview dynamic of cancer immunotherapy.

Cancer is one of the leading causes of death worldwide causing approximately 1 in every 7 deaths. In 2012, 8.2 million people died of the disease with 14 million new cases recorded in that year (WHO Figures). In 2030, the number of new cancer cases is projected to be >22 million (50-70% increase) due to the increasing population age and size. 

Cancer immunotherapy (active and passive) aims to harness the body’s own immune system in the fight against tumour progression. In the past decade, this strategy has become the most promising in the search for novel cancer therapies. Recent breakthroughs include either tumour specific/bi-specific monoclonal antibodies (mAbs), checkpoint inhibitors, adoptive cell therapy and therapeutic cancer vaccines (peptides, dendritic cells, allogenic cells, autologous cells, oncolytic viruses). For the latter group, Dendreon’s Provenge® (Sipuleucel-T) was the first therapeutic vaccine approved for any cancer.

*** Please allow up to 48 hours for this product to be dispatched ***

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Advantagene Inc
  • Bavarian Nordic
  • Bioven
  • Gradalis
  • Northwest Biotherapeutics
  • OSE Immunotherapeutics
  • MORE
  • Executive summary
  • Cancer and immunotherapy
  • Cancer immunotherapy: broad approaches
  • Overview
  • Introduction to cancer vaccines
  • Types of cancer vaccines
  • Cancer vaccine approaches: cell-based vaccines
  • Cancer vaccine approaches: peptide-based vaccines
  • Cancer vaccine approaches: DNA vaccines
  • Cancer vaccine approaches: RNA vaccines
  • Cancer vaccine approaches: Viral vector vaccines
  • Cancer vaccine approaches: Oncolytic viruses
  • Approved therapeutic cancer vaccines
  • Provenge® (Sipuleucel-T)
  • Provenge® (Sipuleucel-T): Phase III data
  • Provenge® (Sipuleucel-T): Ongoing trials
  • Current R&D pipeline
  • Cancer vaccines: pipeline analysis methodology
  • Cancer vaccine trials (Phase I-III), by tumour type
  • Cancer vaccine trials, by phase and sponsor type 2016
  • Cancer vaccine trials, by tumour and sponsor type 2016
  • Cancer vaccine trial phases verified 2016 per tumour tissue
  • Cancer vaccine phase III trials per tumour type
  • Cancer vaccine trials conducted for single vs multiple tissue tumours - verified in 2016
  • Industry sponsored Phase II/III and Phase III cancer vaccine trials verified in 2016
  • Melanoma
  • Seviprotimut-L (POL-103A) - Polynoma
  • Seviprotimut-L (POL-103A): Phase II data
  • Prostate Cancer
  • PROSTVAC® (rilimogene galvacirepvac) - Bavarian Nordic
  • PROSTVAC® : Phase II data
  • PROSTVAC® : Phase III trial (ongoing)
  • PROSTVAC® : Key ongoing trials
  • ProstAtak® (AdV-tk) - Advantagene Inc
  • ProstAtak® (AdV-tk) - Phase II trial
  • DCVAC/PCa - Sotio
  • DCVAC/PCa: Phase II data
  • DCVAC/PCa: Key ongoing trials
  • Brain Cancer
  • DCVax®-L - Northwest Biotherapeutics
  • DCVax®-L: Phase I/II DCVax-L Trials
  • DCVax®-L: Key ongoing trials
  • ICT-107 - Immunocellular Therapeutics Ltd
  • ICT-107: Phase II data
  • Ovarian Cancer
  • Vigil® (gemogenovatucel-T, FANGTM) - Gradalis
  • Vigil®: Phase II data
  • Vigil®: Key ongoing trials
  • Colon Cancer
  • ALLOSTIM® - Immunovative Therapies Ltd
  • ALLOSTIM®: Phase I/II data
  • ALLOSTIM®/ Allovax®: Key ongoing trials
  • Lung Cancer
  • Tedopi® (OSE2101) - OSE Immunotherapeutics
  • Tedopi® (OSE-2101, IDM-2101)): Phase II data
  • Vaxira® (Racotumomab-alum, 1E10) - Recombio
  • Vaxira® (Racotumomab-alum, 1E10): Phase II data
  • EGF PTI (BV-NSCLC-002) - Bioven
  • EGF PTI (BV-NSCLC-002): Phase II data
  • HyperAcuteTM (Tergenpumatucel-L) - NewLink Genetics Corporation
  • HyperAcuteTM (Tergenpumatucel-L): Phase II study
  • Future perspectives
  • Cancer vaccines in the Checkpoint Inhibitor age
  • Appendix: Historical analysis since 1991
  • Cancer vaccine trials to date: Historical view since 1991
  • Cancer vaccine trials to date - Result status historical view
  • Cancer Vaccine Trials to Date - Trial phase historical view
  • Cancer Vaccine Trials to Date - Trials conducted for single vs multiple tissue tumours - historical view
  • Cancer vaccine trials - Last verification dates
  • Cancer vaccine trials - Last verification dates 2001-2016 by tissue
  • Cancer vaccines: development history summary
  • Bibliography
  • About us
  • Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Advantagene Inc
  • Bavarian Nordic
  • Bioven
  • Gradalis
  • Immunocellular Therapeutics Ltd
  • Immunovative Therapies Ltd
  • NewLink Genetics Corporation
  • Northwest Biotherapeutics
  • OSE Immunotherapeutics
  • Polynoma
  • Recombio
  • Sotio
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll